Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 270 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 MkjVSpVv[3Srb36gRZN{[Xl? M{TjU|AvP87:TR?= NVjlRpBwOjSq M{nJRYV1cGGwb3y= MVPlcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm NHX1SGozPTd6N{C3PS=>
TE13 NUjDUHRCTnWwY4Tpc44hSXO|YYm= MmroNE4{|ryP NGj1[2EzPGh? NGfj[pp2eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> MorSNlU2Pzl4NkW=
TE13 NUHPRYVKSXCxcITvd4l{KEG|c3H5 NF;i[2cxNjQQvF2= NUnSPGJ[OjSq MXrpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9v NEO5ZlczPTV5OU[2OS=>
MEFs NGXw[IFHfW6ldHnvckBCe3OjeR?= NHPM[5g2|ryP MnTYNVZp MYfpcoNz\WG|ZYOgeIhmKEWSRVOgZZR1[WOqbXXueEwhXGm{IHTlcIl3\XK7IHHu[EB1cGViZX\mbYNq\W6leTDv[kBx\WSnc4ThcEBnd3KvYYTpc44> MWiyOVQ5OjZ|NB?=
SW480  NWrIXXVCTnWwY4Tpc44hSXO|YYm= MXOwMlHPxE1? M2e4SFQ5cA>? MV\EUXNQ MVny[ZZmenOnczDFUXQ> NGTPSYwzPTR|NEm5Oy=>
PC3  MYnGeY5kfGmxbjDBd5NigQ>? NVjsSlM5OC5zzszN NIfYN|c1QGh? MUnEUXNQ NXe4PWR4emW4ZYLz[ZMhTU2W NIrjWFMzPTR|NEm5Oy=>
SW480  M4L4cWZ2dmO2aX;uJGF{e2G7 NYjscIxYOC5zzszN NX7kZpkzPDiq MVLEUXNQ MkTvZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w MXmyOVQ{PDl7Nx?=
PC3  NGLj[I5HfW6ldHnvckBCe3OjeR?= M{f1XlAvOc7:TR?= NIj5NIY1QGh? MWfEUXNQ MoTpZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w MkHQNlU1OzR7OUe=
SW480  NEX6eplHfW6ldHnvckBCe3OjeR?= MXOwMlHPxE1? NIPqb4g1QGh? NHrrT|dFVVOR NXKxT40ycW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= MlrQNlU1OzR7OUe=
PC3  NIfBdJlHfW6ldHnvckBCe3OjeR?= NFO3[WYxNjIQvF2= NGWycWs1QGh? M2ji[2ROW09? NXPyPW9ucW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= NEjmNoYzPTR|NEm5Oy=>
A431 M{jNXGFxd3C2b4Ppd{BCe3OjeR?= NVS3VHB{Oi9zMD:1NE8yODCwTR?= NH[3UYk1QGh? MUPEUXNQ NGT6T3hqdmirYnn0d{B1cGViY3XscEBoem:5dHi= NWn0U4xTOjV|N{GwOlk>
A431 NHfWdZNHfW6ldHnvckBCe3OjeR?= NV3Beo9VPTCwTR?= M2XkcFIwPi9zMj:yOIg> NXTEbHRmTE2VTx?= NF\CNnJi[3SrdnH0[ZMheDJzIHHu[EBqdmirYnn0d{BCXEZ|IHX4dJJme3Orb36= MXyyOVM4OTB4OR?=
MDA-MB-231 M3LBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3K4dlAuPjBybl2= NH[0VIEzPGh? NHWzbJVFVVOR M1TibGlEPTBib3[gNVAxdk1? NGDZ[I0zPTF7MkeyNS=>
MCF7 MoLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqwMVYxOG6P NF2xRYIzPGh? NGHFeGRFVVOR NIn2PVdKSzVyIH;mJFc2dk1? MnvNNlUyQTJ5MkG=
SKOV-3 M3z1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn22NU0yOM7:TR?= M{L2TVI1cA>? Mof2SG1UVw>? NHLjUXZKSzVyIH;mJFUvPs7:TR?= NFzwTYIzPTF4OUS5NS=>
A549 M2XYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3QcZpROS1zMN88US=> MljjNlRp NXzVbY1kTE2VTx?= NHLw[FNKSzVyIH;mJFMvOs7:TR?= MX:yOVE3QTR7MR?=
SKOV-3 NVzVU2h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Dl[FAvOS1zzszN NXfNT2J{PDiq Moi1SG1UVw>? NV:4V|VbUUN3MDDv[kAxNjgQvF2= M4DybVI2OTZ7NEmx
A549 MkjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13V[FAvOS1zzszN M{XweFQ5cA>? M4fjfGROW09? M2jSU2lEPTBib3[gNE4zQM7:TR?= MUSyOVE3QTR7MR?=
SKOV-3 M1iyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\VSo9tOC5yMT2wMlnPxE1? MmfNO|Jp NGjJRmVFVVOR MlTtTWM2OCCxZjCwMlMz|ryP NWPjb4ZjOjVzNkm0PVE>
A549 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ScVAvODFvMD65{txO M1rlb|czcA>? NEDXfYRFVVOR M3jMO2lEPTBib3[gNE4xPs7:TR?= NHTwbHkzPTF4OUS5NS=>
HeLa NEnIZ49HfW6ldHnvckBCe3OjeR?= MYeyOVBvVQ>? NVfIOlNoOT[q Mn3WSG1UVw>? MW\pcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi NIrGelgzPTFzNk[4PC=>
CNE2 NXflR4IxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm1TW1GOTByLU[wNI5O M{PEUlI1NzR6L{eybC=> NHnOUoxqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NW\SUWJLOjR7Nkm5NFE>
PC3 NXzNN|NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j1UFExOC1zMECwcm0> MYeyOIg> MoLQTWM2OCCxZjCzNFBvVQ>? M3;6TlI1QDV2NkW4
LNCaP NXTsZ4JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNFAuOTByMH7N NWPQb3o3OjSq MX\JR|UxKG:oIEOwNI5O MUCyOFg2PDZ3OB?=
HeLa  Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVey{txO NWn4fYxZPDiq M4XTVIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= NH7ZUYMzPDh2NkGzOS=>
HMEC-1  MlnySpVv[3Srb36gRZN{[Xl? NFrlelU{ODCwTR?= MXmyOIg> MV3pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B M2XydVI1PzFyNkOx
HeLa M3fHS2Z2dmO2aX;uJGF{e2G7 NXLIN3NiOW2P MoLoNE42cA>? MULhZo9tcXOqZYOgeIhmKHSxdHHsJGhFSUNiYXP0bZZqfHl? NE\JWYczPDdyN{S3OC=>
ACP02 NGG1SGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zYe|I2OC9|NUCvOVAxdk1? MUCyOIg> MkPi[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? M33KdlI1PjZ6NUS3
ACP03 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFriTWczPTBxM{WwM|UxOG6P NET2fmczPGh? NHvjNGpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgc4Yh[XCycn;4bY1ifGWueTC3NOKhLSCjdDCyOVDDqG6P MoK0NlQ3Pjh3NEe=
U87 GBM MlfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrnO5AyODBxM{CwM|UxOCCwTR?= Mn\6O|IhcA>? M1fVOFExOCViZYToZY5wdA>? MXny[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= NE\SPVQzPDR4NEi0NS=>
U87 GBM M4HYemZ2dmO2aX;uJGF{e2G7 MnnnNVAxNzVyMDDOcS=> Mkm4OFghcA>? MXSxNFAmKGW2aHHuc4w> NECxelRKdmS3Y3XzJHNmdmW|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l? NVmxVIg1OjR2NkS4OFE>
RPE NFPqS|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\0PFAvOi9yLkSvNE45NzFizszN MorSNlQwPDhxN{KgbC=> MYfEUXNQ M2rUbIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 NVPOco82OjR2NU[2NFI>
HT29  M4LWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe1TFgyQDBibl2= NUfYVJBSPzJiaB?= NGC1eYxKSzVyIH;mJFE5OCCwTR?= MVmyOFM3QDJ4NR?=
hMSCs NXHLRWw1TnWwY4Tpc44hSXO|YYm= NYPSfnhkPi5{NTDuUS=> MonDNlQhcA>? MYPEUXNQ NWWxfZRWe3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> NH\lPVAzPDNzMkO1Oi=>
Huh7  Mn7jSpVv[3Srb36gRZN{[Xl? Mn\ONE4yNzBwNT:xMlAh|ryP NFK5UJozPGh? M3HWN5N2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= NXfPOot2OjR{Nkm2O|I>
SKOV3 NITic4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXewMlA2NTJizszN MoLwNVAwOjRxNEigbC=> MXTEUXNQ MoDvcYVlcWG2ZYOg[5Jwf3SqIHHydoV{fCCrbjDhJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MVKyOFIzOzhyMR?=
A2780 NFX1fmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnLbmlKOC5yNT2yJO69VQ>? NELLU5oyOC9{ND:0PEBp Mk\ZSG1UVw>? NG\wW2Vu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NYDNNFRyOjR{MkO4NFE>
SRA01/04  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TkelAvOiEQvF2= MWC0PEBp NEXqZ5ZFVVOR MVXzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MlrVNlQyPTd6N{i=
HLEB3 MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf3RnA3OC5{IN88US=> Mo\IOFghcA>? NUGwSHA2TE2VTx?= M4L0e5N2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NVK1XIlCOjRzNUe4O|g>
SRA01/04  M1r3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYf2WXpqOC52L{CuPEDPxE1? NE\1dG41QCCq MmLmSG1UVw>? NH;iO5RqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MUWyOFE2Pzh5OB?=
HLEB3 NFzJc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlm2NE41NzBwODFOwG0> MUe0PEBp MVzEUXNQ MXnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MXiyOFE2Pzh5OB?=
HCT116 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICyc|YxNjJizszN NIPDdWgyOiCq MoSy[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= M3:5blI1OTJ{MkOx
CA46 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHexPWg{NzZxMUKvNlQwPDhibl2= NXT1TFcyPDhiaB?= NWKze|RNcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= MnvMNlQxPjR7NUG=
PMNs NYXkdo94TnWwY4Tpc44hSXO|YYm= M3jmSFMxKG6P NGf3cJY1QCCq MYjpcohq[mm2czDl[oZmem:leYTvd4l{NCCKRFHDJIFkfGm4aYT5JIFv\CCUYXOgZYN1cX[rdIm= NVf4OXhbOjN7OEi2NVc>
H1299 M1vDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHONeKh|ryPwrC= MYOyOE81QC95MjDo NHvwc3VmfGijbn;s MWnpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> MmLwNlM6OTZ4MEm=
A549 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X0clAvOjVxMD61M|Eh|ryP MV2yOE81QC95MjDo NGHyOFVmfGijbn;s M2PWRYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M33mblI{QDZ5OUmx
H1299 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUS4PZE5OC5{NT:wMlUwOSEQvF2= MUGyOE81QC95MjDo MUXleIhidm:u MWfpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NU\IcoNOOjN6Nke5PVE>
A549 M3n2WGFxd3C2b4Ppd{BCe3OjeR?= MVmwMlUwOSEQvF2= NIXWZ|g1QCCq NE\wS4lmfGijbn;s NVn1NIJbcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M4rhTVI{QDZ5OUmx
H1299 MoP3RZBweHSxc3nzJGF{e2G7 NWjYXHB5OC53L{Gg{txO NWq4c4RIPDhiaB?= MkDt[ZRp[W6xbB?= MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHuwWmUzOzh4N{m5NS=>
SUM149PT MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLQbmg6Oi95LkWvNVAh|ryP NWmwWXpnPDhiaB?= M3TkeGROW09? Mlu1bY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? NF3tbXEzOzd7Mk[zPC=>
SUM190PT NH64d4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;ZWoY2OC9zMECvNlUxKG6P NH:xVlk1QCCq NFfuZY1FVVOR M2jRfYlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? NXHRWm5uOjN5OUK2N|g>
HCT1 NXnETnRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUewMlIwOS5yL{WuNEDPxE1? MoTQNVIwOjRxM{[vOFghcA>? M4r0bYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MVSyN|c4ODByMB?=
Lovo NH3XTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmwMlIwOS5yL{WuNEDPxE1? NEK3cmgyOi9{ND:zOk81QCCq NED2XmNqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MkLTNlM4PzByMEC=
AGS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzUNE4xOTVvMTFOwG0> NWm3WFRwPzJiaB?= NH\HO4dqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> M2GwN|I{PzR3MEK0
Huh7 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYSxJO69VQ>? NHrUSJIzPCCq MYTEUXNQ MnvsdoVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> M1\zWlI{PjR|OUOz
ECC1 NF75WphHfW6ldHnvckBCe3OjeR?= NFvObI02ODBibl2= NHn6Sno2KGR? M3\SdWROW09? MkHNbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? MkG4NlM2OzB5Nkm=
HEC1A M{jYfGZ2dmO2aX;uJGF{e2G7 NIjkVIg2ODBibl2= NYTkNXA4PSCm NFPjb3NFVVOR M4XkW4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MkTaNlM2OzB5Nkm=
EN1 M{LH[mZ2dmO2aX;uJGF{e2G7 MUm1NFAhdk1? MYG1JIQ> NWjXPXdKTE2VTx?= M1zocolv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NV;q[I5nOjN3M{C3Olk>
MFE296 MorzSpVv[3Srb36gRZN{[Xl? MY[1NFAhdk1? MmnMOUBl MV7EUXNQ NVHqcYVscW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NIOwdlAzOzV|MEe2PS=>
HASMCs MVXGeY5kfGmxbjDBd5NigQ>? NVXFXlc1OC13MECgcm0> MWC2JIQ> NFfTcnZld3ewLYLl[5Vt[XSnczD0bIUh\XiycnXzd4lwdiCxZjDIRWREKGGwZDDj[YxtKH[rYXLpcIl1gQ>? NVyydY5GOjN3MUi0Olc>
U373 NUWzbIV[TnWwY4Tpc44hSXO|YYm= NEfqcWIxNjJ3L{CuOU8yKM7:TR?= M{jm[FI1KGh? MXnpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? M4jJe|I{PDd2MUex
ARN8  NYToUmdYTnWwY4Tpc44hSXO|YYm= NWXuSoxtOC5yNT2yJO69VQ>? M4KyZVI1KGh? NUHrb3F3emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NGDqPWczOzR5MEW0NC=>
MCF7 MVHGeY5kfGmxbjDBd5NigQ>? NIiyRXAxNjB3LUKg{txO NH7YSVczPCCq NVvzRWZDemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? M4LJTlI{PDdyNUSw
H1299  NXj6WWV2TnWwY4Tpc44hSXO|YYm= M3H2VVAvOzQkgKOxxsDDvU1? NI[2b5EzPC92ODDo NEi3fpZFVVOR NVnib2hucW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> NVS1XIZtOjN2NkG5O|U>
H1299 MlPySpVv[3Srb36gRZN{[Xl? NV\3dZp7OC53IN88US=> MUO0PEBp NFXoO5NFVVOR MmHabY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> NXfSRYhQOjN2NkG5O|U>
H1299 MlTFSpVv[3Srb36gRZN{[Xl? NXLRTIdOOC53IN88US=> NULE[3d3PDhiaB?= M4\BTmROW09? MXPpcohq[mm2czD0bIUhcW64YYPpeoVv\XO|wrCgZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>? MnPkNlM1PjF7N{W=
MG-63  NXrlO4ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj6NE4{KM7:TR?= MVKxNk06PiCq MXnEUXNQ MXrpcohq[mm2czD0bIUh[2WubDDndo94fGhiY3:teJJm[XSvZX70JJdqfGhibXX0[o9zdWmw NVjmVWFGOjN2NUG4NVc>
LM8 MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0T|MxOC5|IN88US=> NGr4[o0yOi17NjDo MWrEUXNQ MnfDbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= MkS5NlM1PTF6MUe=
K562 NFTsRpVHfW6ldHnvckBCe3OjeR?= NGLNeJExNjVizszN NX[4eFR6OjRiaB?= NV;5Z|dX\XSqYX7vcC=> MmD6[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> M4nGVFI{PDNyOUW3
HEL NF71WHhHfW6ldHnvckBCe3OjeR?= NH36[mkxNjVizszN NWPFdG92OjRiaB?= M4\a[IV1cGGwb3y= NGryW5Rl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? Mn\CNlM1OzB7NUe=
HL60 MY\BdI9xfG:|aYOgRZN{[Xl? MmPVNUDPxE1? M{PZdVI1KGh? M4TIZ4lv\HWlZYRCpINmdGxiZHXheIg> NHnSSHozOzRyMEWxPS=>
KG1 M1nMR2Fxd3C2b4Ppd{BCe3OjeR?= MYOxJO69VQ>? NYHCUZprOjRiaB?= M4iwcIlv\HWlZYRCpINmdGxiZHXheIg> NHTVW2czOzRyMEWxPS=>
Kazumi NF7DbWJCeG:ydH;zbZMhSXO|YYm= MlzENUDPxE1? M2TINFI1KGh? Mk[5bY5lfWOnc9MgZ4VtdCCmZXH0bC=> M17aZlI{PDByNUG5
K562 NHrkVFBCeG:ydH;zbZMhSXO|YYm= MofENUDPxE1? NFvJPGozPCCq M1:zVYlv\HWlZYRCpINmdGxiZHXheIg> MVmyN|QxODVzOR?=
THP1 M{n6NWFxd3C2b4Ppd{BCe3OjeR?= NUjYUplHOSEQvF2= NFvVWW4zPCCq NYDMfYZWcW6mdXPld:Kh[2WubDDk[YF1cA>? M2DpU|I{PDByNUG5
SH-SY5Y MlHQSpVv[3Srb36gRZN{[Xl? MWKyOVAhdk1? NF\MeGwyPiCq NGLYS3pkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 NWnSRXhzOjN|Mk[0NlI>
HEK293 M1\Cb2Z2dmO2aX;uJGF{e2G7 NUT1dYR3OSEEtV5CpC=> NXOzdXJHOThiaNMg NUTDR|lMcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= M1yyblI{Ojh2OES4
HTK M2jMSGZ2dmO2aX;uJGF{e2G7 MVS0NFAhdk1? MmXYO|IhcA>? NHHqN5RqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v Moq4NlMzQDRyMEK=
HTK NX\jXJkzTnWwY4Tpc44hSXO|YYm= MVGxNFAuQDBybl2= M3fzTFczKGh? NUHyZnM4[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= NXzycoJxOjN{OESwNFI>
Caco-2  M{K5c2Z2dmO2aX;uJGF{e2G7 MlPGNUDDvU4EoB?= NYfwRXdTOjRiaB?= NGDqWGdl\WO{ZXHz[ZMhW0WUVDDwdo91\WmwIHX4dJJme3Orb36= MVWyN|E6PTB5MB?=
HeLa NF3HcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWSxNFAhdk1? MYeyOEBp NYTOelBFTE2VTx?= MoPiTWM2OCCxZjCxNFBvVQ>? MlnoNlMyPjV5NEi=
HeLa M2G1dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XMblQxKG6P M2LTfFQ5KGh? M2DncWROW09? Ml7lTWM2OCCxZjC0NI5O Mn\sNlMyPjV5NEi=
HeLa NH3aSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWWyNEBvVQ>? MUK3NkBp NVTGTXVGTE2VTx?= M4TnfmlEPTBib3[gNlBvVQ>? MmPRNlMyPjV5NEi=
HeLa M3P3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYOxNE8{OC93MDDuUS=> NI[0eXE4OiCq NEHHT4xFVVOR NXnYVJVHcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 NH\6fmEzOzF4NUe0PC=>
MDA-MB-231 NXPBfmViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2yOU01ODBibl2= NV7UO2xHPDhiaB?= NWP0ZWtqUUN3MDDv[kAzPjNwMn7NxsA> NHvUWlMzOzB3NUG5PC=>
MCF-7  MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\1SJgzPS12MECgcm0> NVy5ZVdZPDhiaB?= NWrobHRWUUN3MDDv[kAzOjBwNH7N Mk\5NlMxPTVzOUi=
ECC-1  M2XoTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXRUW46OTByIH7N MoDJNlQhcA>? M{GyeYV1cGGwb3y= NWHLSHNscW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl NYO0b|JDOjNyMki4NFM>
HEC-1A NG\Db5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom0NVAxKG6P NGPDeoQzPCCq NFrvRlFmfGijbn;s M{DGcolv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBieG:ydH;0bYMhdnWlbHXpJJRwKDN7JR?= MU[yN|AzQDhyMx?=
NHAC-kn MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDqV4IyOC9zMECvOVAxKG6P NGrmV|AyOiCq M2OyXGROW09? NXvyVIU2UUN3MDDv[kA2ODCwTR?= NF[wOG8zOzBzN{i3NS=>
A549 MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XUV|I2OCCwTR?= MojTOk04OiCq MW\EUXNQ MlXaZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> NInaWnozOjl7NEe4NC=>
MG-63 NF60T4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTqN|AxKG6P M4nXN|EzKGh? MVvEUXNQ NGHTbHlqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn M2X0PFIzPzl7M{O4
MG-63 M2Psb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnONYx{OzByIH7N NXrLT4FyOjRiaB?= MoTBSG1UVw>? M3rm[4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? Ml20NlI4QTl|M{i=
MG-63 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTPN|AxKG6P NIrEVFU1QCCq NIDDSGNFVVOR MYXpcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gOVYm NYTF[Y1WOjJ5OUmzN|g>
HL60  NULINFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TaSFE2OC1|NUCgcm0> NEXjTIgzPCCq NIr0VZlqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O M4[5elIzPzV|N{O5
U937 NYr3bWUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vFdlE2OC1|NUCgcm0> NWD3fnhqOjRiaB?= NFLZUpJqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O M{HM[|IzPzV|N{O5
SCC-6 M2PobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PTcFIxOC1|MkCwJI5O NHfreWEyOi9{ND:0PEBp NEPwZWJFVVOR NWH6XHMycW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MYWyNlU2OjN{MR?=
U87  MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\meWEyODBvM{CwJI5o MYmyOEBp NI\2VWlqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= MXKyNlI4ODh2OR?=
K562 MnP5SpVv[3Srb36gRZN{[Xl? MYixJO69VQ>? NGDnUmkyOiCq MkjmSG1UVw>? NHq4NVFmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NFzPe24zOjF5OUG5PC=>
Reh M1m1ZWZ2dmO2aX;uJGF{e2G7 NIrzN3IxNjNxMTFOwG0> MlLZNVIhcA>? MnXWSG1UVw>? M2HBbYVvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS NIj4PG4zOjF5OUG5PC=>

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4 6 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID